A short teaser for a full podcast episode on YouTube and Spotify that discusses possible effects of GLP-1s past the scale.
Recap by typeshit. Post by Facebook on Facebook.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Good Morning America looks at GLP-1 use spreading from adults to a growing number of teens being treated for obesity.
The anti-doping agency says many sellers use research chemical labels to dodge FDA scrutiny while selling peptides and SARMs.
Loading…